Viracta Therapeutics company info

What does Viracta Therapeutics do?
Viracta Therapeutics (NASDAQ:VIRX) focuses on advancing innovative treatments for patients battling cancer and viral-associated malignancies. The company is dedicated to developing targeted and precise epigenetic therapies, leveraging its proprietary drug platform to disrupt cancer cells' growth and survival mechanisms. Viracta's key projects aim at addressing the unmet medical needs of individuals suffering from various types of lymphoma and solid tumors, with a particular emphasis on Epstein-Barr virus (EBV)-associated diseases. Their objectives include pushing the boundaries of personalized medicine to improve treatment outcomes and enhance the quality of life for cancer patients.
Viracta Therapeutics company media
Company Snapshot

Is Viracta Therapeutics a public or private company?

key
Ownership
Public

How many people does Viracta Therapeutics employ?

people
Employees
40

What sector is Viracta Therapeutics in?

pie chart
Sector
Health Care

Where is the head office for Viracta Therapeutics?

location pin
Head Office
California, United States

What year was Viracta Therapeutics founded?

founded flag
Year Founded
1998
What does Viracta Therapeutics specialise in?
/Cancer Treatment /Epigenetic Technology /Nanatinostat Development /Clinical Trials /Life Sciences /Therapeutic Medicine

What are the products and/or services of Viracta Therapeutics?

Overview of Viracta Therapeutics offerings
Nanatinostat, in combination with valganciclovir, targets Epstein-Barr virus (EBV)-associated cancers.
Pipeline extends to treatments for EBV-positive lymphomas, including diffuse large B-cell lymphoma.
Exploring nanatinostat for potential efficacy in other viral-associated malignancies.
Collaboration with leading oncology institutions for the advancement of viral-associated cancer therapies.
Initiating global clinical trials to extend the reach and impact of nanatinostat treatments.
Focused research on developing novel therapeutic approaches for viruses associated with cancer.

Who is in the executive team of Viracta Therapeutics?

Viracta Therapeutics leadership team
  • Mr. Mark Andrew Rothera
    Mr. Mark Andrew Rothera
    CEO, President & Director
  • Dr. Susan  Perrine M.D.
    Dr. Susan Perrine M.D.
    Scientific Founder and Consultant
  • Dr. Ronald J. Berenson M.D.
    Dr. Ronald J. Berenson M.D.
    Co-Founder and Consultant
  • Mr. George  Hillman
    Mr. George Hillman
    Co-Founder
  • Dr. Thalia  Papayannopoulou M.D.
    Dr. Thalia Papayannopoulou M.D.
    Co-Founder
  • Dr. Robert M. Williams Ph.D.
    Dr. Robert M. Williams Ph.D.
    Co-Founder
  • Dr. Douglas V. Faller M.D., Ph.D.
    Dr. Douglas V. Faller M.D., Ph.D.
    Scientific Founder & Chairman of Scientific Advisory Board
  • Ms. Melody  Burcar CPA, M.B.A.
    Ms. Melody Burcar CPA, M.B.A.
    Senior VP of Finance, Interim Principal Financial Officer & Interim Principal Accounting Officer